The end point of this double-blind ... 1999;82(suppl 4):IV14 IV22. Altered adrenergic receptor sensitivity due to polymorphic variation. Arg389=arginine; Gly389=glycine. Adapted from J Biol ...

Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...

This approval is considered a major breakthrough in treating acute pain without the need for opioid medication as reliance on ...

Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose ...

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

The receptor fold is very similar to that of rhodopsin ... such as those in the highly conserved D/ERY motif at the cytoplasmic end of transmembrane helix 3 or those in transmembrane helix 6 ...

Angiotensin II (AT-II)-Receptor Antagonists are Reviewed. Research focused on blocking the renin- angiotensin system (RAS) led to the discovery of angiotensin-converting-enzyme (ACE) inhibitors ...

Kidney stones are among the possible risks of GLP-1 use that were not previously known. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) may have a wider range of benefits and risks than what ...

A review of key developments and emerging issues in US International Trade Commission (ITC or Commission) unfair import ...

Despite significant financial losses and workforce reductions, Ultimovacs ASA's merger with Zelluna Immunotherapy aims to revolutionize cancer treatment with innovative TCRNK technology.

The Food and Drug Administration approved a new type of nonopioid painkiller, Journaxv, or suzetrigine, drugmaker Vertex ...